Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases

Mingqiang Ren, Haiyan Qin, Ruizhe Ren, Josephine Tidwell, John Kenneth Cowell

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Chromosomal translocations and activation of the fibroblast growth factor (FGF) receptor 1 (FGFR1) are a feature of stem cell leukemia-lymphoma syndrome (SCLL), an aggressive malignancy characterized by rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. It has been suggested that FGFR1 proteins lose their ability to recruit Src kinase, an important mediator of FGFR1 signaling, as a result of the translocations that delete the extended FGFR substrate-2 (FRS2) interacting domain that Src binds. In this study, we report evidence that refutes this hypothesis and reinforces the notion that Src is a critical mediator of signaling from the FGFR1 chimeric fusion genes generated by translocation in SCLL. Src was constitutively active in BaF3 cells expressing exogenous FGFR1 chimeric kinases cultured in vitro as well as in T-cell or B-cell lymphomas they induced in vivo. Residual components of the FRS2-binding site retained in chimeric kinases that were generated by translocation were sufficient to interact with FRS2 and activate Src. The Src kinase inhibitor dasatinib killed transformed BaF3 cells and other established murine leukemia cell lines expressing chimeric FGFR1 kinases, significantly extending the survival of mice with SCLL syndrome. Our results indicated that Src kinase is pathogenically activated in lymphomagenesis induced by FGFR1 fusion genes, implying that Src kinase inhibitors may offer a useful option to treatment of FGFR1-associated myeloproliferative/lymphoma disorders.

Original languageEnglish (US)
Pages (from-to)7312-7322
Number of pages11
JournalCancer Research
Volume71
Issue number23
DOIs
StatePublished - Dec 1 2011

Fingerprint

Fibroblast Growth Factor 1
Fibroblast Growth Factor Receptors
Phosphotransferases
src-Family Kinases
Lymphoma
Leukemia
Stem Cells
Gene Fusion
Receptor, Fibroblast Growth Factor, Type 1
Myeloproliferative Disorders
Genetic Translocation
B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Binding Sites
T-Lymphocytes
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. / Ren, Mingqiang; Qin, Haiyan; Ren, Ruizhe; Tidwell, Josephine; Cowell, John Kenneth.

In: Cancer Research, Vol. 71, No. 23, 01.12.2011, p. 7312-7322.

Research output: Contribution to journalArticle

Ren, Mingqiang ; Qin, Haiyan ; Ren, Ruizhe ; Tidwell, Josephine ; Cowell, John Kenneth. / Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. In: Cancer Research. 2011 ; Vol. 71, No. 23. pp. 7312-7322.
@article{2ffa1b8c1d3d4407ae33a3c1a9568a76,
title = "Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases",
abstract = "Chromosomal translocations and activation of the fibroblast growth factor (FGF) receptor 1 (FGFR1) are a feature of stem cell leukemia-lymphoma syndrome (SCLL), an aggressive malignancy characterized by rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. It has been suggested that FGFR1 proteins lose their ability to recruit Src kinase, an important mediator of FGFR1 signaling, as a result of the translocations that delete the extended FGFR substrate-2 (FRS2) interacting domain that Src binds. In this study, we report evidence that refutes this hypothesis and reinforces the notion that Src is a critical mediator of signaling from the FGFR1 chimeric fusion genes generated by translocation in SCLL. Src was constitutively active in BaF3 cells expressing exogenous FGFR1 chimeric kinases cultured in vitro as well as in T-cell or B-cell lymphomas they induced in vivo. Residual components of the FRS2-binding site retained in chimeric kinases that were generated by translocation were sufficient to interact with FRS2 and activate Src. The Src kinase inhibitor dasatinib killed transformed BaF3 cells and other established murine leukemia cell lines expressing chimeric FGFR1 kinases, significantly extending the survival of mice with SCLL syndrome. Our results indicated that Src kinase is pathogenically activated in lymphomagenesis induced by FGFR1 fusion genes, implying that Src kinase inhibitors may offer a useful option to treatment of FGFR1-associated myeloproliferative/lymphoma disorders.",
author = "Mingqiang Ren and Haiyan Qin and Ruizhe Ren and Josephine Tidwell and Cowell, {John Kenneth}",
year = "2011",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-11-1109",
language = "English (US)",
volume = "71",
pages = "7312--7322",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases

AU - Ren, Mingqiang

AU - Qin, Haiyan

AU - Ren, Ruizhe

AU - Tidwell, Josephine

AU - Cowell, John Kenneth

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Chromosomal translocations and activation of the fibroblast growth factor (FGF) receptor 1 (FGFR1) are a feature of stem cell leukemia-lymphoma syndrome (SCLL), an aggressive malignancy characterized by rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. It has been suggested that FGFR1 proteins lose their ability to recruit Src kinase, an important mediator of FGFR1 signaling, as a result of the translocations that delete the extended FGFR substrate-2 (FRS2) interacting domain that Src binds. In this study, we report evidence that refutes this hypothesis and reinforces the notion that Src is a critical mediator of signaling from the FGFR1 chimeric fusion genes generated by translocation in SCLL. Src was constitutively active in BaF3 cells expressing exogenous FGFR1 chimeric kinases cultured in vitro as well as in T-cell or B-cell lymphomas they induced in vivo. Residual components of the FRS2-binding site retained in chimeric kinases that were generated by translocation were sufficient to interact with FRS2 and activate Src. The Src kinase inhibitor dasatinib killed transformed BaF3 cells and other established murine leukemia cell lines expressing chimeric FGFR1 kinases, significantly extending the survival of mice with SCLL syndrome. Our results indicated that Src kinase is pathogenically activated in lymphomagenesis induced by FGFR1 fusion genes, implying that Src kinase inhibitors may offer a useful option to treatment of FGFR1-associated myeloproliferative/lymphoma disorders.

AB - Chromosomal translocations and activation of the fibroblast growth factor (FGF) receptor 1 (FGFR1) are a feature of stem cell leukemia-lymphoma syndrome (SCLL), an aggressive malignancy characterized by rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. It has been suggested that FGFR1 proteins lose their ability to recruit Src kinase, an important mediator of FGFR1 signaling, as a result of the translocations that delete the extended FGFR substrate-2 (FRS2) interacting domain that Src binds. In this study, we report evidence that refutes this hypothesis and reinforces the notion that Src is a critical mediator of signaling from the FGFR1 chimeric fusion genes generated by translocation in SCLL. Src was constitutively active in BaF3 cells expressing exogenous FGFR1 chimeric kinases cultured in vitro as well as in T-cell or B-cell lymphomas they induced in vivo. Residual components of the FRS2-binding site retained in chimeric kinases that were generated by translocation were sufficient to interact with FRS2 and activate Src. The Src kinase inhibitor dasatinib killed transformed BaF3 cells and other established murine leukemia cell lines expressing chimeric FGFR1 kinases, significantly extending the survival of mice with SCLL syndrome. Our results indicated that Src kinase is pathogenically activated in lymphomagenesis induced by FGFR1 fusion genes, implying that Src kinase inhibitors may offer a useful option to treatment of FGFR1-associated myeloproliferative/lymphoma disorders.

UR - http://www.scopus.com/inward/record.url?scp=82655179976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82655179976&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-1109

DO - 10.1158/0008-5472.CAN-11-1109

M3 - Article

VL - 71

SP - 7312

EP - 7322

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 23

ER -